Bazemore Robert B — SEC Form 4 filings
SEC reporting owner CIK 1620152. 10 Form 4 filings on record with FilingPulse; latest filed 2026-06-18.
Transaction summary — filings shown
Covers all 10 filings on record, filed 2024-06-17 to 2026-06-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 18.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | Director | 4 | — | — | 10 |
| ARDELYX, INC. (ARDX) | Director | 3 | — | — | 5 |
| Nuvation Bio Inc. (NUVB) | Director | 3 | — | — | 3 |
Form 4 filings — Bazemore Robert B
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-18 | 4 | ARDELYX, INC. (ARDX) | Grant/award (A): 26,455 @ $0 · Grant/award (A): 39,715 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | Nuvation Bio Inc. (NUVB) | Grant/award (A): 123,397 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Akari Therapeutics Plc (AKTX) | Purchase (P): 123,731 (derivative) · Purchase (P): 123,731 (derivative) @ $0.40 · Purchase (P): 30,932 (derivative) · Purchase (P): 30,932 (derivative) @ $0.40 | EDGAR |
| 2025-06-23 | 4 | ARDELYX, INC. (ARDX) | Grant/award (A): 41,551 @ $0 · Grant/award (A): 54,059 (derivative) @ $0 | EDGAR |
| 2025-05-23 | 4 | Nuvation Bio Inc. (NUVB) | Grant/award (A): 292,983 (derivative) @ $0 | EDGAR |
| 2025-03-24 | 4 | Akari Therapeutics Plc (AKTX) | Grant/award (A): 175,000 (derivative) @ $0 · Grant/award (A): 225,000 (derivative) @ $0 | EDGAR |
| 2025-03-10 | 4 | Akari Therapeutics Plc (AKTX) | Grant/award (A): 44,642 @ $1.12 · Grant/award (A): 44,642 (derivative) @ $1.12 · Grant/award (A): 44,642 (derivative) @ $1.12 | EDGAR |
| 2024-09-18 | 4 | Akari Therapeutics Plc (AKTX) | Grant/award (A): 5,000,000 (derivative) @ $0 | EDGAR |
| 2024-09-05 | 4 | Nuvation Bio Inc. (NUVB) | Grant/award (A): 200,801 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | ARDELYX, INC. (ARDX) | Grant/award (A): 40,243 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1620152 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →